Hepatitis C: A Pharmacological Therapeutic Update
Resumen: (1) Background: Hepatitis C is a high-prevalence disease, representing a global impact health problem. Lately, many changes have been made in treatment guidelines because of the commercialization of second-generation direct-acting antivirals due to their high effectiveness, few side effects and pangenotypic action. We address the pharmacological possibilities available and compare them with the current recommendations of the World Health Organization (WHO). (2) Methods: The search for articles was made through the PubMed database using different search strategies and we consulted technical data sheets of the treatments that have been included in the study. (3) Results: Combinations of “glecaprevir/pibrentasvir”, “sofosbuvir/velpatasvir” and “sofosbuvir/velpatasvir/voxilaprevir” have been recently incorporated. Phase II studies have shown that they are safe and effective therapies with very comfortable posologies and easy therapeutic adherence; furthermore, they suppose shorter treatment duration. Subsequently, phase III studies have shown they were effective for previously treated or compensated cirrhotic patients that previously had more complex treatment regimens. (4) Conclusions: These results suppose a simplification in Hepatitis C therapeutic approach, and open new study possibilities.
Idioma: Inglés
DOI: 10.3390/jcm10081568
Año: 2021
Publicado en: Journal of Clinical Medicine 10, 8 (2021), 1568
ISSN: 2077-0383

Factor impacto JCR: 4.964 (2021)
Categ. JCR: MEDICINE, GENERAL & INTERNAL rank: 55 / 172 = 0.32 (2021) - Q2 - T1
Factor impacto CITESCORE: 4.4 - Medicine (Q2)

Factor impacto SCIMAGO: 1.04 - Medicine (miscellaneous) (Q1)

Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Area Anatom.Embriol.Humana (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Farmacología (Dpto. Farmac.Fisiol.y Med.L.F.)


Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.


Exportado de SIDERAL (2025-01-13-14:27:56)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Anatomía y Embriología Humana
Artículos > Artículos por área > Farmacología
Artículos > Artículos por área > Medicina



 Registro creado el 2025-01-13, última modificación el 2025-01-14


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)